Ozempic vs Wegovy vs Mounjaro: which is which?

Ozempic vs Wegovy vs Mounjaro: the short version

The comparison of Ozempic vs Wegovy vs Mounjaro confuses many people because the names are often used interchangeably online. In fact, Ozempic and Wegovy contain the same active ingredient, semaglutide, made by the same manufacturer, but they are approved for different purposes and come in different dose ranges. Mounjaro contains a different ingredient, tirzepatide, which works on two hormone pathways instead of one.

You may also hear about Zepbound. Zepbound is tirzepatide branded specifically for weight management in some countries, such as the United States. In Korea, tirzepatide is marketed as Mounjaro. The medicine inside Mounjaro and Zepbound is the same.

Side-by-side comparison

The points below summarize the main differences. They describe general prescribing information; your doctor will consider your individual situation.

• Active ingredient: Ozempic is semaglutide; Wegovy is semaglutide; Mounjaro is tirzepatide
• How it works: Ozempic and Wegovy activate the GLP-1 receptor; Mounjaro activates both GIP and GLP-1 receptors
• Main approved use: Ozempic for type 2 diabetes; Wegovy for chronic weight management and, in some countries, reducing cardiovascular risk in people with heart disease and excess weight; Mounjaro for type 2 diabetes, and in Korea and some other countries also for weight management
• Dose range: Ozempic usually up to 2 mg weekly; Wegovy steps up to 2.4 mg weekly; Mounjaro steps from 2.5 mg up to 15 mg weekly
• Injection: all three are once-weekly pens injected under the skin of the abdomen, thigh or upper arm
• Weight loss in trials: tirzepatide produced greater average weight loss than semaglutide in head-to-head research, though individual responses vary
• Side effects: all share similar digestive effects such as nausea, diarrhea and constipation, and the same thyroid C-cell tumor warning
• Weight-focused relatives: Wegovy is the weight-focused semaglutide brand; Zepbound is the weight-focused tirzepatide brand in some countries

Why the same molecule has two brand names

Ozempic was first developed and approved to improve blood sugar control in type 2 diabetes. During trials, people also lost weight, which led to higher-dose studies specifically for obesity. Those studies supported Wegovy, which reaches a higher weekly dose of semaglutide and is approved for weight management in people with or without diabetes.

Using Ozempic off-label for weight loss became common worldwide and contributed to shortages for people with diabetes. At VEI Clinic, we prescribe according to the approved use that fits your condition. If your main goal is weight management, Wegovy or tirzepatide is usually the more appropriate choice.

Availability can also shape the decision. Supply of particular strengths has at times been limited worldwide, and not every brand or dose is sold in every country. If you started treatment abroad, bring your pen or prescription so we can match the ingredient and dose as closely as possible, or plan a safe switch if your usual product is not available in Korea.

How we help you choose

There is no single right option for everyone. Dr. HyunSung Park, an internal medicine specialist, considers several factors when recommending a medicine:

• Whether you have type 2 diabetes, prediabetes or insulin resistance
• Your BMI, waist size and weight-related conditions such as high blood pressure or fatty liver
• How you have tolerated GLP-1 medicines in the past, if at all
• Other medicines you take, including insulin, sulfonylureas or oral contraceptives
• Your budget, travel plans and how follow-up will work
• Any reasons not to use these medicines, such as a family history of medullary thyroid cancer

Who should not take any of these medicines

Semaglutide and tirzepatide share important cautions. They should not be used if you or a family member have had medullary thyroid carcinoma or MEN2, during pregnancy, when trying to conceive or while breastfeeding. A history of pancreatitis, gallbladder disease, severe digestive disorders or diabetic eye disease needs careful review first.

People who take insulin or a sulfonylurea for diabetes need dose adjustments, as combining these with semaglutide or tirzepatide raises the risk of low blood sugar. Anyone with diabetic retinopathy should have their eyes monitored, because rapid improvement in blood sugar can temporarily worsen it.

Seek urgent medical help, or call 119 in Korea, if you develop severe abdominal pain spreading to your back, persistent vomiting, fainting, or signs of a serious allergic reaction while using any of these medicines.